Orforglipron vs. Oral Semaglutide Phase 3 Trial Compares Efficacy in Type 2 Diabetes

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Despite existing treatments like metformin, many patients struggle to achieve optimal glycemic control, increasing risks of cardiovascular and renal complications. Glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized T2D management due to their glucose-dependent insulinotropic effects, weight loss, and cardiovascular benefits. While injectable GLP-1R agonists are effective, oral formulations like semaglutide offer convenience, and novel oral small-molecule agonists like orforglipron aim to further improve accessibility and patient adherence. This trial investigates if Orforglipron can match or exceed the efficacy of oral Semaglutide.

The ACHIEVE-3 study is a Phase 3, randomized, open-label trial involving 1698 adult participants with Type 2 Diabetes whose glycemic control was inadequate with metformin. Participants were randomized to receive once-daily oral Orforglipron (at two different dose levels) or once-daily oral Semaglutide (at two different dose levels). The study duration is approximately 61 weeks. The primary endpoint is the change from baseline in Hemoglobin A1c (HbA1c) at Week 52, assessing both efficacy and safety of Orforglipron compared to oral Semaglutide.